147 Results

People

  1. Horwitz
    Horwitz
  2. Salles
    Salles
  3. Usmani
    Usmani
  4. Zelenetz
    Zelenetz
  5. Kumar
    Kumar
  6. Perales
    Perales
  7. Batlevi
    Batlevi
  8. Moskowitz
    Moskowitz
  9. Palomba
    Palomba
  10. Shah
    Shah

Groups

  1. Department of Medicine (118)
  2. Hematologic Malignancies, Division of (74)
  3. Solid Tumor Oncology Division (61)
  4. Center for Hematologic Malignancies (53)
  5. Epidemiology and Biostatistics (26)
  6. Lymphoma (25)
  7. Weinberg Fellows (25)
  8. Biostatistics Service (23)
  9. Population Sciences Research Program (21)
  10. Survivorship Research (21)
  1. "overall response rate"
Formats
  1. Journal Article (114)
  2. Editorial (10)
  3. Review (8)
  4. Correspondence (6)
  5. Research Letter (6)
  6. Meeting Abstract (2)
  7. Guidelines (1)
Groups
  1. Department of Medicine (118)
  2. Hematologic Malignancies, Division of (74)
  3. Solid Tumor Oncology Division (61)
  4. Center for Hematologic Malignancies (53)
  5. Epidemiology and Biostatistics (26)
  6. Lymphoma (25)

More Groups

People
  1. Andrew Zelenetz (9)
  2. Gilles Salles (9)
  3. Saad Usmani (9)
  4. Steven Horwitz (9)
  5. Anita Kumar (8)
  6. Miguel-Angel Perales (8)

More People

Years
  1. 2025 (23)
  2. 2024 (41)
  3. 2023 (32)
  4. 2022 (27)
  5. 2021 (17)
  6. 2020 (6)

More Years

Publications
  1. Leukemia and Lymphoma (13)
  2. Blood (10)
  3. Haematologica (9)
  4. ESMO Open (7)
  5. Leukemia (7)
  6. Annals of Oncology (6)

More Publications

Publishers
  1. Elsevier Inc. (25)
  2. Nature Publishing Group (19)
  3. American Society of Hematology (16)
  4. Taylor & Francis Group (13)
  5. Oxford University Press (11)
  6. Ferrata Storti Foundation (9)

More Publishers

Results (147)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: A phase 1 trial
    Journal Article

    Bullock, A. J.; Schlechter, B. L.; Fakih, M. G.; Tsimberidou, A. M.; Grossman, J. E.; Gordon, M. S.; Wilky, B. A.; Pimentel, A.; Mahadevan, D.; Balmanoukian, A. S.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • COLUMBIA-1: A randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
    Journal Article

    Segal, N. H.; Tie, J.; Kopetz, S.; Ducreux, M.; Chen, E.; Dienstmann, R.; Hollebecque, A.; Reilley, M. J.; Elez, E.; Cosaert, J.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: The phase 1b BRUIN trial
    Journal Article

    Roeker, L. E.; Woyach, J. A.; Cheah, C. Y.; Coombs, C. C.; Shah, N. N.; Wierda, W. G.; Patel, M. R.; Lamanna, N.; Tsai, D. E.; Nair, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1-resistant mucosal melanoma
    Journal Article

    Lochrin, S. E.; Cugliari, M. K.; Yeh, R.; Shoushtari, A. N.
    Melanoma Research (2024)

    Fulltext@MSK | Save
  • Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
    Journal Article

    Fontana, E.; Rosen, E.; Lee, E. K.; Højgaard, M.; Mettu, N. B.; Lheureux, S.; Carneiro, B. A.; Cote, G. M.; Carter, L.; Plummer, R.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save
  • The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: Using clinical judgement over treatment criteria
    Journal Article

    Apolo, A. B.; Bellmunt, J.; Cordes, L.; Gupta, S.; Powles, T.; Rosenberg, J. E.; Van Der Heijden, M. S.
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: Retrospective study from the Ultra-Rare Sarcoma Working Group
    Journal Article

    Giani, C.; Denu, R. A.; Ljevar, S.; Gronchi, A.; Napolitano, A.; Rosenbaum, E.; Salawu, A.; Bajpai, J.; Connolly, E. A.; Lee, A. T. J.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Effect of time-of-day nivolumab and stereotactic body radiotherapy in metastatic head and neck squamous cell carcinoma: A secondary analysis of a prospective randomized trial
    Journal Article

    Janopaul-Naylor, J. R.; Boe, L.; Yu, Y.; Sherman, E. J.; Pfister, D. G.; Lee, N. Y.; McBride, S.
    Head & Neck (2024)

    Fulltext@MSK | Save
  • Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
    Editorial

    Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors
    Journal Article

    Barker, C. A.; D'Angelo, S. P.; Wasilewski, G.; Steckler, A. M.; Lian, M.; Zhang, Z.; Chapman, P. B.; Shoushtari, A. N.; Ariyan, C. E.
    Radiotherapy and Oncology (2024)

    Fulltext@MSK | Save